To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of nilutamide and to compare this agent with the currently marketed nonsteroidal antiandrogens (i.e., bicalutamide, flutamide) by critically analyzing the published literature.
DATA SOURCES:
MEDLINE (1980–1995) and CANCERLIT (1991–1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination with prostatic neoplasms.
STUDY SELECTION AND DATA EXTRACTION:
All articles with subject matter on nilutamide, bicalutamide, and flutamide were considered for inclusion. For studies published in more than one journal, the first publication was used unless a subsequent publication included additional or follow-up data, in which case the latter publication was cited instead.
DATA SYNTHESIS:
Nilutamide was effective in combination with orchiectomy in improving responses in patients with advanced prostate cancer. However, patient survival was not improved in these trials, and improvements in bone pain did not usually result in improved performance status in these patients. The few trials of nilutamide monotherapy or nilutamide in combination with a luteinizing hormone-releasing hormone analog are too small to draw meaningful conclusions regarding its efficacy or its role in the treatment of advanced prostate cancer. No comparative trials of nilutamide with other antiandrogens and no analysis of the impact of nilutamide on patient quality of life are currently available. Nilutamide appears to produce a higher frequency of adverse effects than the other currently marketed nonsteroidal antiandrogens, bicalutamide and flutamide.
CONCLUSIONS:
Nilutamide does not appear to represent a major advance in the treatment of advanced prostate cancer and appears to be somewhat inferior to both flutamide and bicalutamide with regard to adverse effects. Nilutamide should not be considered the antiandrogen of choice in the treatment of advanced prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
ParkerSLTongTBoldenSWingoPA. Cancer statistics, 1996. CA Cancer J Clin1996; 65: 5–27.
2.
HugginsCHodgesCV. Studies of prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res1941; 1: 293–7.
3.
CatalonaWJ. Management of cancer of the prostate. N Engl J Med1994; 331: 996–1004.
4.
BhanalaphTVarkarakisMJMurphyGP. Current status of bilateral adrenalectomy for advanced prostatic carcinoma. Ann Surg1974; 179: 17–23.
5.
MacFarlaneDAThomasLPHarrisonJH. A survey of total adrenalectomy in cancer of the prostate. Am J Surg1960; 99: 562–72.
6.
IsaacsJTWakeNCoffeyDSSandbergAA. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-337 rat prostatic adenocarcinoma system. Cancer Res1982; 42: 2353–61.
7.
IsaacsJTCoffeyDS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res1981; 41: 5070–5.
8.
GellerJde la VegaDJAlbertJDNachtsheimDA. Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab1984; 58: 36–40.
9.
The Leuprolide Study Group.Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med1984; 311: 1281–6.
10.
WarnerBWorgulTJDragoJDemersLDufauMMaxD. Effect of very high dose d-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic—pituitary testicular axis in patients with prostate cancer. J Clin Invest1983; 71: 1842–53.
11.
PeelingWB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbesterol in treatment of prostatic carcinoma. Urology1989; 33 (Suppl 5):45–52.
12.
MoguilewskyMFietJTournemineCRaynaudJP. Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem1986; 24: 139–46.
13.
NeriRKassemN. Biological and clinical properties of antiandrogens. In: BrescianiFKingRJBLippmanMENamerMRaynaudJP, eds. Progress in cancer research and therapeutics. New York: Raven Press, 1984; 31: 507–18.
14.
BelandGElhilaliMFradetYLarocheBRamseyEWTrachtenbergJ. Total androgen ablation: Canadian experience. Urol Clin North Am1991; 18: 75–82.
15.
HarperMEPikeAPeelingWBGriffithsK. Steroids of adrenal origin metabolized by human prostate tissue both in vivo and in vitro. J Endocrinol1974; 60: 117–25.
16.
DaneshgariFCrawfordED. Endocrine therapy of advanced carcinoma of the prostate. Cancer1993; 71: 1089–97.
SolowayMSMatzkinH. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer1993; 71: 1083–8.
19.
KuhnJMBillebaudTNavratilHMoulonguetAFietJGriseP. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med1989; 321: 413–8.
20.
FietJHussonJMBertagnaCHucherMRaynaudJP. Endocrine effects during the first six months of treatment with a pure antiandrogen Anandron (RU 23908) in castrated patients with advanced prostate cancer (abstract). J Steroid Biochem1986; 25 (Suppl 1):75S.
21.
BelangerADupontALabrieF. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J Clin Endocrinol Metab1984; 59: 422–6.
22.
FietJDoreJCGoALOjasooTRaynaudJP. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. Prostate1993; 23: 291–313.
23.
DecensiATorrisiRMarroniPPensaFPadovaniPBoccardoF. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. Prostate1994; 24: 17–23.
24.
Gaillard-MoguilewskyM. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology1991; 37 (suppl):5–12.
CreavenPJPendyalaLTremblayD. Pharmacokinetics and metabolism of nilutamide. Urology1991; 37 (suppl): 13–9.
27.
McKillopDBoyleGWCockshottIDJonesDCPhillipsPJYatesRA. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica1993; 23: 1241–53.
28.
KatchenBBuxbaumS. Disposition of a new, nonsteroid antiandrogen α,α,α-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (flutamide) in men following a single oral 200 mg dose. J Clin Endocrinol Metab1975; 41: 373–9.
29.
PendyalaLCreavenPJHubenRTremblayDBertagnaC. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. Cancer Chemother Pharmacol1988; 22: 69–76.
30.
RaynaudJPFietJLeGoffJMMartinPMMoguilewskyMOjasooT. Design of antiandrogens and their mechanisms of action: A case study (Anandron). Horm Res1987; 28: 230–41.
31.
CockshottIDSotaniemiEACooperKJJonesDC. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol1993; 36: 339–43.
32.
BrissetJMBoccon-GibodLBottoHCameyMCariouGDuclosJM. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: A multicenter comparative study of two doses of a drug and a placebo. Prog Clin Bio Res1987; 243A: 411–22.
33.
NamerMToubolJCatyACouetteJEDouchezJKerbratP. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol1990; 37: 909–15.
34.
BelandGElhilaliMFradetYLarocheBRamseyETrachtenbergJ. A controlled trial of castration with and without nilutamide in metastatic prostate cancer. Cancer1990; 66 (Suppl 5): 1074–9.
35.
JanknegtRAAbbouCCBartolettiRBernstein-HahnLBrackenBBrissetJM. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol1993; 149: 77–82.
36.
CrawfordEDNaborsWL. Total androgen ablation: American experience. Urol Clin North Am1991; 18: 55–63.
37.
BertangaCDe GeryAAHucherMFrancoisJPZaniratoJ. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostate cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol1994; 73: 396–402.
38.
Prostate Cancer Trialists' Collaborative Group.Maximum androgen blockade in advanced cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet1995; 346: 265–9.
39.
McLeodDGBensonRCEisenbergerMACrawfordEDBlumensteinBASpicerD. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer1993; 72: 3870–3.
40.
NavratilH. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Prog Clin Biol Res1987; 243A: 401–10.
41.
DenisLJde MouraCarneiro JLBonoASylvesterRWhelanPNewlingD. Goserelin acetate and flutamide versus bilateral orchiectomy: A Phase III EORTC trial (30853). Urology1993; 42: 119–30.
42.
Iversen P, Rasmussen F, Klarskov P, Christensen IJ, for the Danish Prostatic Cancer Group.Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostatic cancer. Cancer1993; 72 (suppl):3851–4.
43.
CrawfordEDEisenbergerMAMcLeodDGSpauldingDTBensonRDorrFA. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med1989; 321: 419–24.
44.
DenisL. Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice?Prostate1995; 27: 233–40.
45.
SchellhammerPSharifiRBlockNSolowayMVennerPPattersonAL. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology1996; 47 (Suppl 1A):54–60.
46.
ScherHIKellyWK. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol1993; 11: 1566–72.
47.
NiehPT. Withdrawal phenomenon with the antiandrogen Casodex. J Urol1995; 153: 1070–3.
48.
DecensiAUBoccardoFGuameriDPositanoNPaolettiMCCostantini. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol1991; 146: 377–81.
49.
KolvenbagGJCMBlackledgeGRP. Worldwide activity and safety of bicalutamide: A summary review. Urology1996; 47 (Suppl 1A):70–9.
50.
LundFRasmussenF. Flutamide versus stilboestrol in the management of advanced prostatic cancer: A controlled prospective study. Br J Urol1988; 61: 140–2.
51.
SolowayMSSchellhammerPFSmithJAChodakGWKennealeyGT. Bicalutamide in the treatment of advanced prostatic carcinoma: A Phase II multicenter trial. Urology1996; 47 (Suppl 1A):33–7.
52.
ChodakGSharifiRKasimisBBlockNLMaCramallaEKennealeyGT. Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995; 46: 849–55.
53.
BalesGTChodakGW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996; 47: 38–43.
54.
BlackledgeGRP. High-dose monotherapy for the treatment of prostate cancer. Urology1996; 47: 44–7.
55.
SchroderFH. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Prog Clin Biol Res1990; 359: 93–103.
56.
HarnoisCMalenfantMDupontALabrieF. Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Opthalmol1986; 70: 471–3.
57.
PfitzenmeyerPFoucherPPiradFCoudertBBraudMLGabezP. Nilutamide pneumonitis: A report on eight patients. Thorax1992; 47: 622–7.
58.
AkounGMLioteHALioteFGauthier-RahmanSKuntzD. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis. Chest1990; 97: 495–8.
59.
GomezJLDupontACusanLTremblayMTremblayMLabrieF. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): A case report. Am J Med1992; 92: 563–6.
60.
SeigneurJTrechotPFHubertJLamyP. Pulmonary complications of hormone treatment in prostate carcinoma. Chest1988; 93: 1106.
61.
BergerVBersonAWolfCChachatyCFauDFromentyB. Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: Possible role in the development of lung lesions in patients treated with this antiandrogen. Biochem Pharmacol1992; 43: 654–7.
62.
BrogdenRNClissoldSP. Flutamide: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostate cancer. Drugs1989; 38: 185–203.
63.
SoganiPCVagaiwalaMRWhitmoreWFJr. Experience with flutamide with advanced prostatic cancer without prior endocrine therapy. Cancer1984; 54: 744–50.
64.
ProutGRJrKeatingMAGriffinPPSchiffSF. Long-term experience with flutamide in patients with prostatic carcinoma. Urology1989; 34 (suppl):37–45.
